




**EUROPEAN RENAL ASSOCIATION**

EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION

Registered Charity n° 1000124

XLVIII  
**era-edta**  
congress  
prague - czech republic  
june 23-26, 2011

**ABSTRACTS ON CD-ROM**



the production of this  
CD-ROM has been  
supported by

**AMGEN**

**Nephrology**

Study for Discs of Newton  
František Kupka, 1911-1912 gouache, watercolour on paper  
28.5 x 28.5 cm  
From the Museum Kampa  
"The Jan and Meda Mladek Foundation"

[www.eraedta2011.org](http://www.eraedta2011.org)

**[F307] THE ITALIAN REGISTRY FOR APHERESIS**

**Stefano Passalacqua,<sup>1</sup> Emilio Staffolani,<sup>2</sup> Paola Brescia,<sup>3</sup> Carmelo Loschiavo,<sup>3</sup> Elena Mancini,<sup>3</sup> Giulio Monaci,<sup>3</sup> Gaspare Elios Russo,<sup>3</sup> Alfonso Ramunni<sup>3</sup>.** <sup>1</sup>Department of Nephrology, C.I. Columbus-UCSC, Rome, Italy; <sup>2</sup>Section of Nephrology, University of Tor Vergata, Rome, Italy; <sup>3</sup>Apheresis Study Group, Italian Society of Nephrology, Rome, Italy

**INTRODUCTION AND AIMS:**

There is currently no consensus about the indications for therapeutic apheresis, also due to the lack of large clinical trials. A registry where all the data can be organized and analyzed therefore becomes a priority for all professionals involved in apheresis.

**METHODS:**

The Apheresis Study Group of the Italian Society of Nephrology has instituted a registry for data collection. This report describes data collected from 1994 to 2010 by 89 units of different specialties in 18/20 Italian regions.

**RESULTS:**

Data about 36,093 treatments on 3,097 patients were recorded. Plasma exchange accounted for 40.7% of the procedures; 34.3% of these were performed by filtration. Plasma treatment was used in 48.8% of procedures, in particular with protein A immunoabsorption (8.9%), LDL-cholesterol apheresis by dextran sulfate adsorption (13.9%), and semiselective cascade or double filtration (13.9%). Cell apheresis, limited to photopheresis and leukocytapheresis, was used in 4.9% of cases, and whole blood treatment, with different techniques, in 5.7% of cases for the treatment of dyslipidemia, liver failure and sepsis. These procedures account for about 20% of the estimated therapeutic apheresis performed in Italy according to the national survey performed for the year 2005 by the Italian Apheresis and Cell Manipulation Society.

**CONCLUSIONS:**

The data collected are sufficiently informative to show a definite trend to use plasma/whole blood treatments as often as possible. The registry not only is a tool for consultation and information, but also a platform to plan and realize interdisciplinary and multicenter clinical trials.

**Date:** Friday, June 24, 2011

**Session Info:** Poster Session: Extracorporeal dialysis: techniques and adequacy

[Close Window](#)